Nivolumab is a dud, just look at their response rates. but still it rakes in mind numbing dollars every year because there are very few alternatives once the standard care of treatment is exhausted. those who can get a response out of it would be grateful it buys more time until the next treatment. if Nox can provide a greater response rate, this would provide an opportunity to augment a massive player already inside the game further their grip on market share.
NOX Price at posting:
64.5¢ Sentiment: Buy Disclosure: Held
